Ann: 2023 Annual Report to shareholders, page-182

personally I think the discussion should be more focused on the company pathway for the next:

1 month - results
3 months - digestion of results
6+ months - decision time regarding the results.

I feel talk about what $$ everyone is after really doesnt help shape any meaningful thought.

However, discussions of what Neuren will be doing over the next 6 months will be the main factor that determines any price...for better or worse.

Like a lot here, ive been invested for 7+ years and for me its all been leading up to PhII value for NNZ - Ive always thought (and continue to now) that Neuren just cant/wont continue further down this path.

IMO once they have demonstrated the potential of the drug - ie the PhII results for these 4 indications - I feel we will all know the fate of Neuren.

As usual, good luck to holders !